Glp-1 Analogues Market Size, Share, By Product (Ozempic, Trulicity, Mounjaro, Xultophy, Victoza, Saxenda, and Others), By Drug Class (Semaglutide, Dulaglutide, Liraglutide, and Exenatide), By Route of Administration (Parenteral, and Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI554024 | Publish Date: July 2024 | No. of Pages: 178

Glp 1 Analogues Market Companies

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi
  • AstraZeneca
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Pfizer.Inc
  • Amgen, Inc.
  • Innovent Biologics, Inc.
  • PegBio Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Zealand Pharma
  • Moderna
  • Hanmi Science

Recent News:

  • Viking's new dual GLP-1R/GIPR agonist is planned to enter phase III clinical trials as early as July 2024. VK2735 could be a direct competition for Eli Lilly's Mounjaro. Viking Therapeutics, an American biopharmaceutical company, is researching several candidates for treating metabolic illnesses. VK2735, a dual glucagon-like peptide-1 receptor (GLP-1R)/gastric inhibitory polypeptide (GIP) receptor agonist, is being tested as a weekly subcutaneous (SC) injection and an oral tablet for obesity management.
  • In July 2024, the MHRA authorized Semaglutide, a GLP-1 receptor agonist, to reduce the risk of serious cardiac problems in obese or overweight persons. Semaglutide is the first weight-loss medicine approved in the United Kingdom as a preventative treatment for adults with pre-existing cardiovascular disease. This GLP-1 receptor agonist has already been licensed for use in treating obesity and weight management in conjunction with diet, physical activity, and behavioral support.